Eton (ETON) Q2 Revenue Jumps 108%
Eton Pharmaceuticals (NASDAQ:ETON), a biopharmaceutical company focused on rare diseases, posted earnings for Q2 2025 on August 7, 2025. The main highlight was a strong revenue increase from both core and recently acquired products. GAAP revenue of $18.9 million surpassed consensus expectations by $2.2 million, up 108% from the same period last year. Non-GAAP earnings per share (EPS) reached $0.03, topping the $0.02 estimate and swinging into positive territory on a non-GAAP basis from a non-GAAP loss in Q2 2024. The company's continued product sales growth, margin expansion, and successful launches contributed to an overall positive quarter.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Eton Pharmaceuticals specializes in the development and commercialization of therapies for rare diseases. Its portfolio includes multiple treatments for conditions with serious unmet needs, such as severe primary insulin-like growth factor 1 (IGF-1) deficiency and adrenal insufficiency. The company focuses on niche patient populations, allowing it to develop strong relationships with specialist healthcare providers and patient advocacy groups.
Source Fool.com
